Results 111 to 120 of about 72,405 (280)

Beyond the gut: Non‐specific interstitial pneumonia in pediatric ulcerative colitis—A rare extra‐intestinal manifestation

open access: yesJPGN Reports, EarlyView.
Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disorder often presenting with extra‐intestinal manifestations (EIMs) involving the skin, joints and eyes. However, pulmonary manifestation, such as interstitial lung disease (ILD), is a rare complication, particularly in the pediatric population. We report a case of a 10‐year‐old boy,
Harshit Vachher   +5 more
wiley   +1 more source

Infliximab to treat Crohn’s disease: an update

open access: yes, 2011
M Cottone, V CriscuoliBiomedical Department of Internal and Specialist Medicine, Division of Medicine, Villa Sofia-V Cervello Hospital, Palermo University, Palermo, ItalyAbstract: Crohn’s disease (CD) is a chronic inflammatory disease of the ...
Criscuoli V, Cottone M
core  

Novel pathogenic variant in haploinsufficiency of A20 with severe gastrointestinal effects and fulminant hepatic failure: A pediatric case series

open access: yesJPGN Reports, EarlyView.
Abstract Haploinsufficiency of A20 (HA20) is a rare autoinflammatory disorder caused by heterozygous loss‐of‐function variants in tumor necrosis factor alpha‐induced protein 3 (TNFAIP3), encoding a negative regulator of nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NFκB) signaling.
Amanda Blake   +5 more
wiley   +1 more source

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres   +4 more
wiley   +1 more source

Medically refractory neurosarcoidosis treated with infliximab.

open access: yes, 2011
Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a
Bergin, P   +11 more
core   +1 more source

Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study

open access: yesJEADV Clinical Practice, EarlyView.
This post‐hoc analysis of the Greek real‐world ReSOLVE study compared clinical and patient‐reported outcomes by body weight (< 100 kg vs. ≥ 100 kg) and BMI over 52 weeks. Patients ≥ 100 kg showed delayed PASI and sPGA responses at W24 and W52, while BMI had little impact. Quality‐of‐life improvements were substantial, though early gains were smaller in
Pantelis Panagakis   +12 more
wiley   +1 more source

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman   +5 more
wiley   +1 more source

Erythrodermic, recalcitrant psoriasis: Clinical resolution with infliximab

open access: yes, 2003
This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab.
Kirsner, Robert   +13 more
core   +1 more source

Pembrolizumab‐Induced Subacute Cutaneous Lupus Erythematosus: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Subacute cutaneous lupus erythematosus (SCLE) is an increasingly recognized cutaneous immune‐related adverse event of immune checkpoint inhibitors. We report an 83‐year‐old woman who developed pruritic annular and polycyclic plaques 10 weeks after starting pembrolizumab for oropharyngeal squamous cell carcinoma.
Sebastiano Posenato   +5 more
wiley   +1 more source

Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data

open access: yesТерапевтический архив, 2009
Aim. To analyse the data on infliximab administration (efficacy, tolerance, toxicity) in patients with rheumatoid arthritis (RA) in Russia by clinical evidence provided by the multicenter observation trial. Material and methods. The register included 297
Galina Viktorovna Lukina   +5 more
doaj  

Home - About - Disclaimer - Privacy